Ben Allal

1.1k total citations
32 papers, 918 citations indexed

About

Ben Allal is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Ben Allal has authored 32 papers receiving a total of 918 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 14 papers in Oncology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Ben Allal's work include HER2/EGFR in Cancer Research (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Ben Allal is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Ben Allal collaborates with scholars based in France, United States and Italy. Ben Allal's co-authors include Gilles Favre, Anne Pradines, Bettina Couderc, Philippe Rochaix, Jean‐Pierre Delord, Étienne Chatelut, Pierre Canal, Isabelle Hennebelle, Fabienne Thomas and R. Bugat and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Cancer Research.

In The Last Decade

Ben Allal

31 papers receiving 903 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ben Allal France	20	489	347	139	132	93	32	918
Bea Pauwels Belgium	16	439 0.9×	356 1.0×	188 1.4×	209 1.6×	87 0.9×	30	949
Michelle L. Kraus United States	7	466 1.0×	447 1.3×	129 0.9×	124 0.9×	63 0.7×	9	1.1k
Linda Kessler United States	14	746 1.5×	352 1.0×	75 0.5×	106 0.8×	73 0.8×	38	1.1k
Maureen H. Beresini United States	22	560 1.1×	200 0.6×	168 1.2×	112 0.8×	135 1.5×	34	1.2k
Johannes Bange Germany	10	966 2.0×	420 1.2×	211 1.5×	140 1.1×	102 1.1×	17	1.4k
Alex J. Eustace Ireland	20	688 1.4×	429 1.2×	347 2.5×	163 1.2×	93 1.0×	52	1.2k
Victoria J. Spanswick United Kingdom	21	914 1.9×	462 1.3×	258 1.9×	94 0.7×	58 0.6×	39	1.3k
Julia Kirshner United States	15	368 0.8×	379 1.1×	97 0.7×	75 0.6×	166 1.8×	30	848
Masao Iwata Japan	11	976 2.0×	294 0.8×	220 1.6×	209 1.6×	51 0.5×	13	1.6k
A. M. Burger United States	15	799 1.6×	368 1.1×	158 1.1×	92 0.7×	41 0.4×	30	1.2k

Countries citing papers authored by Ben Allal

Since Specialization

Citations

This map shows the geographic impact of Ben Allal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ben Allal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ben Allal more than expected).

Fields of papers citing papers by Ben Allal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ben Allal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ben Allal. The network helps show where Ben Allal may publish in the future.

Co-authorship network of co-authors of Ben Allal

This figure shows the co-authorship network connecting the top 25 collaborators of Ben Allal. A scholar is included among the top collaborators of Ben Allal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ben Allal. Ben Allal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ysebaert, Loïc, Caroline Protin, Lucie Obéric, et al.. (2025). Ibrutinib pharmacokinetics in B-lymphoproliferative disorders discloses exposure-related incidence of hypertension. Journal of Hypertension. 43(3). 521–528. 1 indexed citations

Valentin, Thibaud, Marie Lambert, Léonor Chaltiel, et al.. (2023). Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide. European Journal of Pharmaceutical Sciences. 185. 106420–106420.

Thomas, Fabienne, Mélanie White‐Koning, Ben Allal, et al.. (2021). Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data. Pharmaceuticals. 14(2). 162–162. 4 indexed citations

Ysebaert, Loïc, Fabien Despas, Sandra De Barros, et al.. (2020). Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. Clinical Pharmacokinetics. 59(9). 1171–1183. 15 indexed citations

Alix‐Panabières, Catherine, Thierry Lafont, Ben Allal, et al.. (2019). Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients. British Journal of Clinical Pharmacology. 85(6). 1357–1366. 19 indexed citations

Soulès, Régis, Emilie Huc‐Claustre, Philippe de Médina, et al.. (2019). A fast UPLC–HILIC method for an accurate quantiﬁcation of dendrogenin A in human tissues. The Journal of Steroid Biochemistry and Molecular Biology. 194. 105447–105447. 6 indexed citations

Puisset, Florent, et al.. (2018). Simultaneous monitoring of pazopanib and its metabolites by UPLC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 154. 373–383. 12 indexed citations

Arellano, Cécile, et al.. (2014). An UPLC–MS/MS method for separation and accurate quantification of tamoxifen and its metabolites isomers. Journal of Pharmaceutical and Biomedical Analysis. 100. 254–261. 17 indexed citations

Vergèz, S., Jean‐Pierre Delord, Fabienne Thomas, et al.. (2010). Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro- D -glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer. Clinical Cancer Research. 16(17). 4434–4445. 20 indexed citations

10.

Dalenc, Florence, Sophie Doisneau-Sixou, Ben Allal, et al.. (2010). Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis. Clinical Cancer Research. 16(4). 1264–1271. 21 indexed citations

11.

Delord, J.P., Stéphane Quideau, Philippe Rochaix, et al.. (2010). Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model. British Journal of Cancer. 103(1). 61–72. 11 indexed citations

12.

Delord, J.P., Marie‐Jeanne Pillaire, Philippe Rochaix, et al.. (2008). Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. British Journal of Cancer. 98(1). 120–128. 42 indexed citations

13.

Couderc, Bettina, Anne Pradines, Arash Rafii, et al.. (2008). In vivo restoration of RhoB expression leads to ovarian tumor regression. Cancer Gene Therapy. 15(7). 456–464. 50 indexed citations

14.

Thomas, Fabienne, Philippe Rochaix, A. Benlyazid, et al.. (2007). Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 13(23). 7086–7092. 54 indexed citations

15.

Delord, Jean‐Pierre, Philippe Rochaix, Fabienne Thomas, et al.. (2005). In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemotherapy and Pharmacology. 57(6). 709–718. 84 indexed citations

16.

Mazières, Julien, Vanessa Tillement, Ben Allal, et al.. (2004). Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. Experimental Cell Research. 304(2). 354–364. 47 indexed citations

17.

Pradines, Anne, et al.. (1999). Epidermal Growth Factor Stimulates 3-Hydroxy-3-Methylglutaryl-coenzyme A Reductase Expression via the ErbB-2 Pathway in Human Breast Adenocarcinoma Cells. Biochemical and Biophysical Research Communications. 260(3). 699–706. 28 indexed citations

18.

Allal, Ben, et al.. (1998). SupraMolecular BioVectors (SMBV) improve antisense inhibition of erbB-2 expression. British Journal of Cancer. 77(9). 1448–1453. 10 indexed citations

19.

Allal, Ben, Eric Lazartigues, Christine Brefel‐Courbon, et al.. (1998). Central cardiovascular effects of tacrine in the conscious dog: a role for catecholamines and vasopressin release. European Journal of Pharmacology. 348(2-3). 191–198. 4 indexed citations

20.

Sixou, Sophie, et al.. (1997). Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular BioVector (SMBV). Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1355(1). 7–19. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact